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Dopamine (DA) release in striatum is governed by firing rates of midbrain DA neurons, striatal cholinergic tone, and nicotinic ACh
receptors (nAChRs) on DA presynaptic terminals. DA neurons selectively express 6* nAChRs, which show high ACh and nicotine
sensitivity. Tohelp identify nAChRsubtypes that controlDA transmission,we studied transgenicmice expressinghypersensitive6L9S*
receptors. 6L9S mice are hyperactive, travel greater distance, exhibit increased ambulatory behaviors such as walking, turning, and
rearing, and showdecreasedpausing, hanging, drinking, andgrooming.These effectsweremediatedby64*pentamers, as6L9Smice
lacking4 subunits displayed essentially normal behavior. In6L9Smice, receptor numbers are normal, but loss of4 subunits leads to
fewer and less sensitive 6* receptors. Gain-of-function nicotine-stimulated DA release from striatal synaptosomes requires 4 sub-
units, implicating 642* nAChRs in 6L9S mouse behaviors. In brain slices, we applied electrochemical measurements to study
control of DA release by 6L9S nAChRs. Burst stimulation of DA fibers elicited increased DA release relative to single action potentials
selectively in 6L9S, but not WT or 4KO/6L9S, mice. Thus, increased nAChR activity, like decreased activity, leads to enhanced
extracellular DA release during phasic firing. Burstsmay directly enhance DA release from6L9S presynaptic terminals, as there was no
difference in striatal DA receptor numbers or DA transporter levels or function in vitro. These results implicate 642* nAChRs in
cholinergic control of DA transmission, and strongly suggest that these receptors are candidate drug targets for disorders involving the
DA system.
Introduction
Dopamine (DA) transmission, both at cell bodies situated in the
midbrain and at presynaptic terminals in the striatum and pre-
frontal cortex, is tightly regulated by cholinergic systems. Patients
with neural disorders involving DA signaling may benefit from
therapies that augment or reduce cholinergic control over DA
release. For example, stimulating DA release from residual DA
terminals with nicotinic ACh receptor (nAChR) agonists may be
an effective treatment for Parkinson’s disease (PD) (Quik and
McIntosh, 2006). Conversely, the use of antagonists or weak par-
tial agonists at midbrain nAChRs may be an effective strategy for
smoking cessation drugs such as varenicline (Coe et al., 2005).
Developing and further refining such agonists, however, requires
a better understanding of the cell biology and physiology of par-
ticular nAChR subtypes.
Midbrain DA neurons and other cells in local and long-range
circuits that directly synapse onto DA neurons express distinct
nAChR subtypes on their cell surface. GABAergic cells in the
substantia nigra pars reticulata and the ventral tegmental area
(VTA) express 42* (* indicates that other nAChR subunits
may be present) nAChRs receptors with at least two sensitivities
to ACh and nicotine (Nashmi et al., 2007; Xiao et al., 2009).
Midbrain DA neurons express as many as seven distinct nAChR
subtypes or stoichiometric variants: (4)3(2)2, (4)2(2)3,
425, 62, 623, 642, and 6423 (Gotti et al.,
2005; Salminen et al., 2007). 2 subunits are strictly required for
nAChR function in midbrain DA neurons (Picciotto et al., 1998;
Maskos et al., 2005); 4 subunits are expressed in nearly all DA
neurons, and loss of 4 subunits eliminates 80% of surface
nAChRs in these cells (Azam et al., 2002; Marubio et al., 2003;
Nashmi et al., 2007; Xiao et al., 2009). Functional 6* nAChRs
are highly and selectively expressed inDAneurons (Drenan et al.,
2008b), where they assemble with 2, and often, 3 and/or 4
subunits (Champtiaux et al., 2002, 2003; Cui et al., 2003; Drenan
et al., 2008a).
Previous studies indicate that 6423 nAChR pentamers
are important regulators of DA release. For instance, studies on
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nicotine-evoked DA release from striatal synaptosomes indicate
that 6423 nAChRs have the highest sensitivity to nicotine
(EC50  230 nM) (Salminen et al., 2007). Because nicotine
reaches a concentration of 100–500 nM in brain CSF during cig-
arette smoking, 6423 nAChRs on DA neurons are most
likely to respond. We recently constructed mice expressing gain-
of-function 6L9S* receptors to amplify and isolate behavioral
and physiological responses resultant from 6* nAChR activa-
tion (Drenan et al., 2008b). These mice exhibit marked locomo-
tor hyperactivity due to enhanced sensitivity of DA neuron firing
and/or release in response to low concentrations of nicotine or
ACh. To further study the partially overlapping functions of 6*,
4*, and 64* nAChRs, we crossed 4 knock-out (KO) mice
with 6L9S mice. This strain of mice discriminates, for the first
time in vivo, between 642* and 6(non-4)2* nAChRs.
Here we describe experiments showing that 4 subunits are crit-
ical for 6*-mediated behavioral phenotypes. Furthermore, us-
ing electrochemical measurements, we show that DA release
kinetics are significantly altered in 6L9S mice, and that this al-
teration depends on 642* nAChRs.
Materials andMethods
Mice. All experiments were conducted in accordance with the guidelines
for care and use of animals provided by the Office of Laboratory Animal
Welfare at the National Institutes of Health, and protocols were ap-
proved by the Institutional Animal Care and Use Committee at the Cal-
ifornia Institute of Technology or the University of Colorado at Boulder.
Mice were kept on a standard 12/12 or 13/11 h light/dark cycle at 22°C
and given food and water ad libitum. On postnatal day 21, mice were
weaned and housed with same-sex littermates. At 21–28 d, tail biopsies
were taken for genotype analysis by PCR. Tails were digested in 50 mM
NaOH at 95°C for 45 min followed by neutralization with 0.5 M Tris-Cl,
pH 5.5, and subsequent direct analysis by multiplex PCR. 6L9S mice
were generated as described previously (Drenan et al., 2008b) and were
backcrossed to C57BL/6 six to eight times. All studies described here use
“line 2” 6L9S mice (Drenan et al., 2008b). 4KO/6L9S mice were
generated by first crossing 4KO (Ross et al., 2000) mice with 6L9S
mice to generate 4//6L9S mice, which were crossed again to 4KO
mice to produce 4KO/6L9S progeny. Mice of this genotype were con-
tinually backcrossed to 4KO, and the presence of the 6L9S transgene
and the 4 null mutation was independently confirmed for each mouse
using PCR. 4KO mice used in this study were littermates of 4KO/
6L9S mice, and wild-type (WT) control mice were littermates of6L9S
transgenic mice. All groups of mice in this study contained approxi-
mately equal numbers of males and females.
Mouse locomotor activity. Mice used to study locomotion were 8–16
weeks old at the beginning of an experiment. Backcrossing to C57BL/6
did not affect locomotor activity (data not shown). Horizontal locomo-
tor activity was measured with an infrared photobeam activity cage sys-
tem (San Diego Instruments). Ambulation events were recorded when
two contiguous photobeams were broken in succession. Acute locomo-
tor activity in response to nicotine was studied by recording ambulation
events during four 15 s intervals per minute for a designated number of
minutes. For most experiments, groups of eight mice were placed in
activity cages (18  28 cm) and their baseline level of activity was re-
corded for 8 min. Mice were removed from their cage, injected (100 l
per 25 g of body mass), and returned to the cage within 15 s. For gener-
ation of locomotor activity dose–response relationships, a group of mice
was administered saline and, after 5–8 d off, each successive dose of drug.
For 48 h home cagemonitoring,mice were isolated in their own cage and
habituated to the test room and cage for 24 h. Following this, locomotor
activity was recorded in 15 min intervals for 48 h.
Automated mouse behavior analysis. Video-based software analysis of
home cage behavior was conducted as described previously (Steele et al.,
2007). Mice that were normally group housed were singly caged and
habituated to the video recording room and a fresh home cage for 24 h
before recording. The video recording began the following day (2 h be-
fore the dark phase) and continued for 23.5–24.0 h, using dim red lights
for recording during the dark phase. The videos were analyzed using the
definitions and settings described (Steele et al., 2007) using HomeCag-
eScan 3.0 software (Clever Sys) (see Fig. 2A). The visualization in Figure
2A was created in Matlab. The sample sizes were as follows: WT, n 8;
6L9S, n 21; 4KO, n 14; 4KO/6L9S, n 13.
Fast scan cyclic voltammetry in striatal slices. Mice (postnatal day 60–
90) were anesthetized with sodium pentobarbital (40 mg/kg, i.p.) fol-
lowed by cardiac perfusion with oxygenated (95% O2/5% CO2) ice-cold
glycerol-based artificial CSF (gACSF) containing 252 mM glycerol, 1.6
mM KCl, 1.2 mM NaH2PO4, 1.2 mM MgCl2, 2.4 mM CaCl2, 18 mM
NaHCO3, and 11mM glucose. Following perfusion, brains were removed
and retained in gACSF (0–4°C). Coronal slices (300m)were cut with a
microslicer (DTK-1000; Ted Pella) at a frequency setting of 9 and a speed
setting of 3.25. Brain slices were allowed to recover for at least 1 h at 32°C
in regular, oxygenated artificial CSF (ACSF) containing 126 mM NaCl,
1.6 mM KCl, 1.2 mM NaH2PO4, 1.2 mM MgCl2, 2.4 mM CaCl2, 18 mM
NaHCO3, and 11mM glucose. Coordinates for recordings in the caudate/
putamen (CPu) were within the following range: (0.0 to1.0 mm from
bregma,3.0 to4.0 mm from the surface, and1.0 to3.0 from the
midline).
Carbon fiber (7 m, unsized; Goodfellow) electrodes were fabricated
at Caltech using anodic electrodeposition of paint (Schulte and Chow,
1996; Akopian et al., 2008). Voltammetry data were acquired with a
Multiclamp 700A amplifier (Molecular Devices). The command micro-
electrode potential was 400 mV (against a Ag/AgCl reference elec-
trode), and the potential was scanned from 400 mV to 1000 mV to
400mV at a rate of 300mV/ms; ramp frequency was 10Hz. Dopamine
release was elicited by stimulating DA fibers with a bipolar stimulating
electrode (FHC), placed 200–300 m from the recording site. The stim-
ulus (0.65mA, 250s) elicitedmaximal release, and stimulus trains were
generated with an Anapulse Stimulator (World Precision Instruments).
Elicitingmaximal release reduced variability across experiments bymax-
imizing the number of fibers carrying action potentials in the vicinity of
the recording site (Cragg, 2003). When tested, all DA release responses
were blocked by tetrodotoxin (data not shown). Pulse trains were deliv-
ered at 100Hz, similar to themaximal firing rate ofDAneurons observed
in mammals (Rice and Cragg, 2004; Zhang and Sulzer, 2004). A fresh
carbon fiber surface was exposed each recording day. Voltammetry pro-
tocols were initially run for30min to allow the background currents to
settle to an optimal waveform, and were run continually throughout the
day when stimulation protocols were not run. Background currents were
subtracted from signals acquired during striatal stimulation to isolate
transient neurotransmitter release events. DA release recovered fully
within 2min after stimulus trains, and trains were typically delivered at 3
min intervals. Each day, electrodes were calibrated against DA standards
in solution (2.5 and 5.0MDA). Absolute DA concentrations for release
responses in slices were determined using these standards. We hold to
convention and indicate pulse trains by 1p, 2p, etc.; individual pulses
within a train are indicated as p1, p2, etc. For paired-pulse experiments,
responses to 1p and 2p (100 Hz) stimulation were recorded. Release due
to the second of a pair of pulses (p2) was isolated by subtracting the
response to a single pulse (p1, i.e., 1p) from the response to a 2p train.
Dopamine release from striatal synaptosomes. After a mouse was killed
by cervical dislocation, its brain was removed and placed immediately on
an ice-cold platform and brain regions were dissected. Tissues from each
mouse were homogenized in 0.5 ml of ice-cold 0.32 M sucrose buffered
with 5 mMHEPES, pH 7.5. A crude synaptosomal pellet was prepared by
centrifugation at 12,000 g for 20 min. The pellets were resuspended in
“uptake buffer”: 128 mM NaCl, 2.4 mM KCl, 3.2 mM CaCl2, 1.2 mM
KH2PO4, 1.2 mM MgSO4, 25 mM HEPES, 10 mM glucose, 1 mM ascorbic
acid, and 10 M pargyline at pH 7.5. Synaptosomes were incubated at
37°C in uptake buffer for 10 min before addition of 100 nM [3H]-
dopamine (1 Ci per 0.2 ml of synaptosomes), and the suspension was
incubated for an additional 5 min.
All experiments were conducted at room temperature using methods
described previously (Nashmi et al., 2007; Salminen et al., 2007) with
modifications for collection into 96-well plates. In brief, aliquots of syn-
aptosomes (80 l) were distributed onto filters and perfused with buffer
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[uptake buffer containing 0.1% bovine serum albumin (BSA), 1 M at-
ropine, and 1 M nomifensine at 0.7 ml/min for 10 min, or buffer for 5
min followed by buffer with 50 nM CtxMII]. Aliquots of synaptosomes
were then exposed to nicotine in buffer for 20 s to stimulate release of
[ 3H]dopamine followed by buffer. Fractions (0.1 ml) were collected
for 4 min into 96-well plates every 10 s starting from 1 min before stim-
ulation, using aGilson FC204 fraction collectorwith amulticolumn adapter
(Gilson). Radioactivity was determined by scintillation counting using a
1450MicroBeta Trilux scintillation counter (PerkinElmer Life Sciences) af-
ter additionof 0.15mlofOptiphase ‘SuperMix’ scintillation cocktail. Instru-
ment efficiency was 40%.
Data were analyzed using SigmaPlot 5.0 for DOS. Perfusion data were
plotted as counts per minute (cpm) versus fraction number. Fractions
collected before and after the peak were used to calculate baseline as a
single-exponential decay. The calculated baseline was subtracted from
the experimental data. Fractions that exceeded baseline by 10% or more
were summed to give total released cpm and then normalized to baseline
to give units of release [(cpm  baseline)/baseline] (Salminen et al.,
2007).
Dopamine uptake. Synaptosomes were prepared as described for DA
release assays. Synaptosomeswere suspended in uptake buffer (described
above) at a concentration of 8ml permouse for dorsal striatum (ST) and
4ml per mouse for olfactory tubercle (OT). For each well, synaptosomes
(25l) were incubated in uptake buffer (final volume 100l) with either
0.05Mor 1M [3H]dopamine at 22°C for 5min.Nomifensine (100M)
was used for blank determination. The reaction was terminated by filtra-
tion onto a two layer filter consisting of one sheet ofGFA/Eglass fiber filter
(Gelman Sciences) one sheet of GF/B glass fiber filter (Micro Filtration Sys-
tems) both soaked in uptake buffer. Samples were washed with cold uptake
buffer four times. Radioactivity was measured using a Wallac 1450 Micro-
Beta scintillation counter (PerkinElmer Life andAnalytical Sciences) after
addition of 50 l of Optiphase Supermix scintillation cocktail
(PerkinElmer Life Sciences) to each well of a 96-well counting plate.
Previously, we have determinedKM concentration of DA for uptake into
striatal synaptosomes of C57BL/6 mice to be 0.080 0.003M (data not
shown).
Ligand binding. Kd values for each radioligand were determined by
saturation binding to membranes prepared from C57BL/6 mice (data
not shown). All protein determinations were done by the Lowry method
with bovine serum albumin (BSA) as standard.
Previously published methods (Marks et al., 2006; Brown et al., 2007)
were followed to measure high-affinity [ 125I]epibatidine (2200 Ci/
mmol) binding to membrane preparations using a 96-well plate format.
Briefly, membranes treated with phenylmethylsulfonyl fluoride (1 mM)
were incubated with [ 125I]epibatidine (200 pM; Kd 40 pM) in binding
buffer [30 l volume including: 144 mMNaCl, 1.5 mM KCl, 2 mM CaCl2,
1 mMMgSO4, 20 mMHEPES, pH 7.5 with BSA (0.1%w/v), 5 mM EDTA,
5 mM EGTA, 10 g/ml each aprotinin, leupeptin trifluoroacetate, and
pepstatin A]. To some samples,CtxMII (100 nM) was added tomeasure
CtxMII-sensitive epibatidine binding by subtraction from total binding
[the 62*-nAChR population (see Salminen et al., 2005)]. Nonspecific
binding was determined by including L-nicotine (1 mM). Plates were
incubated for 2 h at 22°C.
The D1/D5 dopamine receptors were measured bymembrane binding
of [ 3H]SCH23390 ([N-methyl- 3H]; 70–87 Ci/mmol).Membrane prep-
arations were incubated in binding buffer (30 l volume including the
following: 144 mMNaCl, 1.5 mM KCl, 2 mM CaCl2, 1 mMMgSO4, 20 mM
HEPES, pH 7.5) with [ 3H]SCH23390 used at 1.7 nM (Kd0.1 nM), with
0.5Mmianserin added to block binding to 5-HT2 receptors, and 10mM
flupenthixol added for blank determination. Samples were incubated for
60 min at 22°C. The D2/D3 dopamine receptors were measured with
[ 3H]raclopride ([methoxy- 3H]; 60–87 Ci/mmol). The procedure was
the same as for D1/D5 sites using [
3H]raclopride at 17 nM, (Kd 2 nM)
with 10 M sulpiride added for blank determination. Incubation was for
60 min at 22°C. The dopamine transporter (DAT) was measured by
binding of [ 3H]mazindol (15–30 Ci/mmol) at 200 nM (Kd25 nM) with
addition of 1 M fluoxetine to block the serotonin transporter and 100
nM desipramine to block norepinephrine transporters. Blanks were de-
termined using 100M nomifensine. Samples were incubated for 90min
at 22°C followed by 30 min at 4°C.
For all membrane binding assays, reactions were terminated by
filtration of samples at 4°C onto a two layer filter consisting of one
sheet of GFA/E glass fiber filter (Gelman Sciences) and one sheet of
GF/B glass fiber filter (Micro Filtration Systems) both treated with
0.5% polyethylenimine using an Inotech Cell Harvester (Inotech).
Samples were subsequently washed six times with ice-cold binding buffer.
Radioactivity was measured using a Wallac 1450 MicroBeta scintillation
counter (PerkinElmer Life and Analytical Sciences) after addition of 50
l of Optiphase Supermix scintillation cocktail (PerkinElmer Life Sci-
ences) to each well of a 96-well counting plate.
Statistical analysis. Home cage locomotor ambulation data were ana-
lyzed for significance with a one-way ANOVA with Tukey post hoc anal-
ysis (Drenan et al., 2008b). For automated mouse behavior analysis
(AMBA) behavioral experiments, data were analyzed for significance
with a two-tailedWilcoxon rank-sum test (nonparametric) (Steele et al.,
2007). nAChR ligand binding, DA receptor ligand binding, DAT ligand
binding, andDAT uptake data were analyzed for significance with a t test
within a brain region (ST or OT) and within a genetic background (WT
or 4KO). Synaptosomal DA release curves were fit to the Michaelis–
Menten equation (Hill coefficient 1), and Rmax and EC50 values were
evaluated for statistical significance using a t test within a brain region
(ST or OT) and within a genetic background (WT or 4KO). Voltam-
metry data were evaluated for significance with a t test within a genotype,
where 1p and 4p data were compared.
Materials. All radioactive compounds were obtained from PerkinElmer.
CtxMIIwas synthesized as previously described (Cartier et al., 1996).Ultra
centrifugation grade sucrose was obtained fromFisher Chemicals. Sigma-
Aldrich was the source for the following compounds: ascorbic acid, at-
ropine sulfate, bovine serum albumin (BSA), ()-nicotine tartrate,
nomifensine, cytisine, and pargyline. Optiphase ‘SuperMix’ scintillation
fluid was from PerkinElmer Life Sciences.
Results
64* nAChR-mediated locomotion and behavioral analysis
6L9S BAC transgenic mice use the full 6 promoter to drive the
expression of a leucine 9 to serine mutation in the ion channel
pore lining transmembrane (TM2) domain of the 6 nAChR
subunit, rendering them hypersensitive to agonist (Drenan et al.,
2008b). 6L9S mice show robust locomotor hyperactivity in the
home cage and in response to systemic nicotine injections
(Drenan et al., 2008b), thus providing a system with a broad
dynamic range to study further genetic manipulations. We
crossed Chrna4 homozygous null mutant mice (4KO mice)
with6L9Smice, then bred the resultant4//6L9Smicewith
4KO mice again to inactivate both copies of Chrna4. This ma-
nipulation removes several nAChR subtypes: 42 (both high-
sensitivity and low-sensitivity components), 425, 642,
and 6423 receptors, leaving only 623 and 62
nAChRs (a minority, lower-sensitivity subtype) (Fig. 1A). These
mice (4KO/6L9S) are viable, fertile, and exhibit qualitatively
normal social interactions compared to both 6L9S mice and
4KO mice (data not shown). We measured home cage activity
over 48 h for WT, 6L9S, 4KO, and 4KO/6L9S mice. As
previously reported, 6L9S mice exhibit substantial locomotor
hyperactivity relative to WT mice during the dark phase (their
active period) (Fig. 1B), and this difference was highly significant
when total ambulations were quantified (lights off #1: WT,
5860  765 ambulations/15 min; 6L9S, 34,887  6800 ambu-
lations/15 min; p  0.01) (lights on: WT, 2005  301 ambula-
tions/15 min; 6L9S, 4238 723 ambulations/15 min; p	 0.05)
(lights off #2: WT, 5030 616; 6L9S, 35,491 6869; p 0.01)
(Fig. 1C).WT and4KOmice had normal home cage locomotor
activity (Fig. 1B,C). Surprisingly, the home cage hyperactivity in
6L9S mice was completely abolished in 4KO/6L9S animals
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(lights off #1: 4KO, 6057 1392 ambu-
lations/15 min; 4KO/6L9S, 7821 
2225 ambulations/15 min; p 	 0.05)
(lights on: 4KO, 2174  354 ambula-
tions/15 min; 4KO/6L9S, 2056  504
ambulations/15 min; p	 0.05) (lights off
#2: 4KO, 6328  2014; 4KO/6L9S,
7021 2187; p	 0.05 (Fig. 1B,C), reveal-
ing that 4 subunits are required for the
pronounced phenotype seen in 6L9S
mice.
6L9S mice are hypersensitive to nic-
otine, demonstrating locomotor activa-
tion (rather than locomotor suppression
seen in WT mice) in response to low
doses of nicotine and other nAChR li-
gands (Drenan et al., 2008b). In response
to 0.2 mg/kg nicotine, 4KO/6L9S mice
showed only partial locomotor activation
over a 30min time coursewhen compared
to the response seen in 6L9S mice (peak
locomotor response: 6L9S, 93 14 am-
bulations/min; 4KO/6L9S, 53 4 am-
bulations/min) (Fig. 1D). To further
study this effect, we constructed nicotine
dose–response relations for WT, 6L9S,
4KO, and 4KO/6L9S mice. As seen
previously, 6L9S mice demonstrated lo-
comotor activation across a range of
nicotine concentrations that do not sig-
nificantly affect WT mice (Fig. 1E). WT
mice responded only to the highest tested
dose (1.5 mg/kg) with suppression of lo-
comotor activity, and locomotor activity
of 4KO animals was not altered in re-
sponse to the concentrations tested
(Fig. 1E), consistent with previous results
(Tapper et al., 2007). The potency and ef-
ficacy of nicotine were consistently re-
duced in 4KO/6L9S mice compared
to 6L9S mice (Fig. 1E), suggesting the
emergence of alterations in the sensitivity
and/or number of 6* receptors when 4
subunits are removed.
To better understand the altered be-
havior in 6L9S mice and the effect of 4
subunit removal, we extended the behav-
ioral analysis of these mice using AMBA
with a video-based behavioral recognition system. This system
has previously been validated on several mutant mouse strains
that exhibit altered behavior, including mouse models of Hun-
tington’s disease and prion diseases (Steele et al., 2007, 2008).
Mice are singly housed in their standard cage while the AMBA
software analyzes a video feed of the mouse’s activity (Fig.
2A). To verify that AMBA analyses correspond with the beam-
break method (Fig. 1), we analyzed distance traveled with
AMBA. Consistent with the beam-break data (Fig. 1) and our
previous work (Drenan et al., 2008b), there was a dramatic and
statistically significant increase in the mean distance traveled in
6L9S mice compared toWT littermates (WT, 281 28 m/24 h;
6L9S, 2469  535 m/24 h; p  0.05) (Fig. 2B). In contrast, we
observed no statistically significant increase in distance traveled
when 4KO mice were compared to 4KO/6L9S mice, al-
though therewas a trend toward increased distancewith the pres-
ence of the 6L9S BAC transgene (4KO, 344  62 m/24 h;
4KO/6L9S, 1203  568 m/24 h; p 	 0.05) (Fig. 2B). It is not
clear why the 6L9S behavioral hyperactivity phenotype is highly
variable and only partially penetrant (Fig. 2B), but genetic mo-
saicism or epigenetic changes are possible explanations.
We used the power of AMBA to discriminate among several
specific behaviors in the genotypes under investigation. Specific
behaviors were extracted by the HomeCageScan 3.0 software and
expressed as a percentage of total time recorded (percentage of
total frames). Compared to WT littermates, 6L9S mice exhib-
ited robust differences inmedian values for a variety of behaviors.
In particular, 6L9S mice showed the greatest difference from
WT control mice in behaviors of activity or ambulatory move-
ment, including “jump,” “walk,” “stretch,” “turn,” and “rear”
Figure 1. Hyperactivity in6 L9S mice requires4 nAChR subunits. A, Probable receptor subtypes expressed in DA neurons of
mice examined in this study. The three main nicotinic receptor subtypes expressed in DA neurons of WT mice, 6423*,
623*, and42*, are shown.6 L9S mice express6423* and/or623* nAChRs with augmented sensitivity
relative to the other subtypes, and4KO and4KO/6 L9S mice express only623* and/or62* nAChRs. B, C,6 L9S
mice, but not 4KO/6 L9S mice, are hyperactive in their home cage. Horizontal locomotor activity of mice (6 L9S and WT
littermates;4KO/6 L9S and4KO littermates) in their home cage environmentwas recorded over 48 h. Raw locomotor activity
data (number of ambulations/15 min period) are reported (B). Total locomotor activity from ‘‘lights on’’ and ‘‘lights off’’ periods
indicated inBare shown inC for all genotypes.D, Nicotine-mediated locomotor activation in4KO/6 L9Smice is reduced relative
to6 L9Smice. After 8min of baseline locomotor activity,mice (6 L9S and4KO/6 L9S)were injectedwith 0.2mg/kgnicotine
(i.p.). Locomotor activity was recorded for an additional 30 min after injection. Raw locomotor activity data (number of ambula-
tions/min) are reported. E, Dose–response relationship for nicotine-stimulated locomotor activity in WT, 6 L9S, 4KO, and
4KO/6 L9S mice. Mice were administered nicotine at the indicated dose, and total locomotor activity was measured as in D.
Locomotor activity for each mouse was normalized to a saline control injection for the same mouse. Data are expressed as the
percentage of the response to saline (set to 100%). Data are expressed as mean SEM. The number of mice for home cage
locomotor activity experiments was as follows: WT, n 7;6 L9S, n 16;4KO, n 8;4KO/6 L9S, n 8. The number of
mice for nicotine-stimulated locomotor activity experiments was as follows: WT, n 8; 6 L9S, n 8; 4KO, n 8; 4KO/
6 L9S, n 8. All statistically significant comparisons are indicated. **p 0.01.
9880 • J. Neurosci., July 21, 2010 • 30(29):9877–9889 Drenan et al. • Presynaptic6* Nicotinic Receptors
(Fig. 2C).We also noted a large increase in the percentage of time
6L9S mice exhibited “high-velocity,” erratic behaviors that are
poorly resolved at the video camera’s frame rate and by the
AMBA algorithms (Steele et al., 2007). As expected, the 6L9S
mice displayed a corresponding decrease in several relatively in-
active behaviors, such as “pause,” “hang vertical,” “hang cud-
dled,” and “drink” (Fig. 2C). For 6L9S mice relative to WT
littermates, we found a statistically significant difference for nine
behaviors when we compared the percentage of total time spent
exhibiting each behavior. 6L9S mice spent less total time drink-
ing, hanging cuddled, pausing, and grooming (Fig. 2D). In contrast,
6L9S mice spent a greater percentage of total time jumping, turn-
ing, rearing, and walking, as well as more time exhibiting “high-
velocity” behaviors (Fig. 2D). There was also a trend toward
reduced eating and reduced resting in 6L9S mice compared to
WT controls (Fig. 2D).
To study the effect of the 6L9S mutation in the context of a
Chrna4 null mutant background, and to better understand the
locomotor activity change that we noted in Figure 1A, we re-
corded and analyzed the detailed home cage behavior of 4KO
and 4KO/6L9S mice. In contrast to the 6L9S versus WT lit-
termate comparison, we noticed only modest differences in the
median value for the behaviors in AMBA for 4KO/6L9S mice
compared to 4KO controls (Fig. 2C). Furthermore, differences
in eight of the nine behaviors that were statistically significant in
6L9S versus WT were no longer significant in 4KO/6L9S
versus 4KO. Only rearing remained significantly different be-
tween the latter two genotypes (Fig. 2E). In summary, these be-
havioral results show for the first time the importance of 4
subunits in 6* nAChR function in vivo.
Augmented DA release in6L9S mice requires4 subunits
Locomotor hyperactivity is reminiscent of imbalances in striatal
DA reported for other genetic models exhibiting abnormal DA
transmission (Giros et al., 1996; Zhuang et al., 2001). 6*
nAChRs are selectively expressed in SNc and VTA DA neurons
cell bodies and their terminal fields, most notably dorsal and
ventral striatum (Champtiaux et al., 2002, 2003). Although the
Figure 2. AMBA reveals specific behaviors affected by augmented DA release.A, HomeCageScan system for recording and analyzingmouse behavior. Micewere singly housed in and habituated
to a standard cage for video recording (top panel), and HomeCageScan software (bottom panel) analyzed mouse behavior in real time. B,6 L9S mice traveled greater distance thanWT controls.
Distance traveled over 24 h was calculated and plotted for eachWT,6 L9S,4KO, and4KO/6 L9S mouse. C,4 subunits are required for hypersensitive6* nAChRs to alter mouse behavior.
In each of the 4mouse genotypes indicated, AMBAwas used to calculate the percentage of total time that eachmouse spent exhibiting each of 17 specific behaviors.Median values for each behavior
were compared betweengenotypes (6 L9S vsWT;4KO/6 L9S vs4KO), and the fold change inmedian for each behavior of either6 L9S or4KO/6 L9S over its respective control group (WT
or4KO) is expressed via a heatmapwith yellow indicating an increase inmedian value and blue indicating a decrease inmedian value.D, E, Behavioral differences between6 L9S andWT control
mice largely require 4 nAChR subunits. For either 6 L9S versus WT (D) or 4KO/6 L9S versus 4KO (E), the percentage of total time during 24 h that mice spent exhibiting each indicated
behavior is plotted. Two y-axes are used because several behaviors occupy a large fraction of total time and all behaviors could not be displayed effectively on a single y-axis. Data are expressed as
mean SEM. Thenumber ofmice in eachgroupwas as follows:WT,n8;6 L9S,n21;4KO,n13;4KO/6 L9S,n14. All statistically significant comparisons are indicated. *p0.05,
**p 0.01, ***p 0.001.
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primary effect of the L9S mutation is to
augment the function of 6* receptors, it
is possible that the behavioral differences
seen between WT and 6L9S or between
4KO and 4KO/6L9S are due to differ-
ences in receptor expression. To address
this, we quantified the number of 42*
and 62* binding sites using [125I]epi-
batidine in striatum and olfactory tuber-
cle of these mouse lines. We separately
dissected the ST and the OT, thus roughly
separating the nigrostriatal and mesolim-
bic DA pathways (Ikemoto, 2007). We
used CtxMII to separate 42* (MII-
resistant) from62* (MII-sensitive), the
two predominant subtypes in this prepa-
ration. There was no significant difference
in the number (Fig. 3A,D) (ST: WT,
14.2  1.0 fmol/mg protein; 6L9S,
15.1  2.4 fmol/mg protein; p 	 0.05)
(OT: WT, 10.6  1.0 fmol/mg protein;
6L9S, 9.0  0.9 fmol/mg protein; p 	
0.05) or the percentage (Fig. 3B,E) (ST:
WT, 23.7  1.2% MII-sens; 6L9S,
24.0  3.7% MII-sens; p 	 0.05) (OT:
WT, 24.4  2.0% MII-sens; 6L9S,
19.5 1.7%MII-sens; p	 0.05) of62*
binding sites between WT and 6L9S
mice, either in ST or OT, which is consis-
tent with our previous analysis (Drenan et
al., 2008b). In OT, we noticed a small but
significant increase in MII-resistant
(42*) receptors in 6L9S mice (OT:
WT, 32.6  1.3 fmol/mg protein; 6L9S,
37.1  0.5 fmol/mg protein; p  0.01)
(Fig. 3F), but no change in ST (ST: WT, 45.5  1.2 fmol/mg
protein; 6L9S, 47.7 2.6 fmol/mg protein; p	 0.05) (Fig. 3C).
In 4KOmice, there was a 50–60% reduction in 62* receptor
numbers in both brain areas (Fig. 3A,D), consistent with previ-
ous studies (Salminen et al., 2005, 2007). This was accompanied
by a consequent increase in the percentage of MII-sensitive epi-
batidine binding in mice lacking 4 subunits compared to WT
and6L9S mice (Fig. 3B,E).We noted traceMII-resistant epiba-
tidine binding in4KOand4KO/6L9S ST andOT (Fig. 3C,F),
which may represent a minor population of 4* nAChRs (Klink
et al., 2001; Azam et al., 2002; Gahring et al., 2004). In both ST
(Fig. 3A) and OT (Fig. 3D), there was a further reduction in
62* receptors in 4KO/6L9S tissue compared to 4KO (ST:
4KO, 6.0  0.5 fmol/mg protein; 4KO/6L9S, 2.9  0.4
fmol/mg protein; p  0.001) (OT: 4KO, 2.9  0.5 fmol/mg
protein; 4KO/6L9S, 1.5 0.2 fmol/mg protein; p 0.05), but
this did not correspond to any significance difference in the per-
centage of MII-sensitive binding sites in either of these brain
areas (ST: 4KO, 61.1  1.5% MII-sens; 4KO/6L9S, 57.0 
3.1% MII-sens; p 	 0.05) (OT: 4KO, 41.8  4.6% MII-sens;
4KO/6L9S, 34.9  4.0% MII-sens; p 	 0.05) (Fig. 3B,E).
There was a small difference in MII-resistant binding in ST for
4KO/6L9S versus 4KO mice (ST: 4KO, 3.8 0.3 fmol/mg
protein;4KO/6L9S, 2.2 0.3 fmol/mg protein; p 0.01) (Fig.
3C), but not in OT (OT: 4KO, 4.1  0.6 fmol/mg protein;
4KO/6L9S, 2.8  0.2 fmol/mg protein; p 	 0.05) (Fig. 3F).
Thus, receptor expressionmay account for a fraction of the effect
seen in behavioral assays comparing 4KO versus 4KO/6L9S
mice, but not WT versus 6L9S mice.
Functional aspects of presynaptic 4* and 6* nAChRs are
effectively studied using agonist-evoked DA release from stri-
atal synaptosomes (Grady et al., 2002). To study native
nAChRs on DA terminals, we prepared synaptosomes from
WT, 6L9S, 4KO, and 4KO/6L9S mice and measured
nicotine-stimulated DA release. To separate responses depen-
dent on 6-containing from 4(non-6)-containing nAChRs,
we blocked 6* nAChRs with CtxMII as described previously
(Salminen et al., 2004, 2007). Inmeasurements onOT tissue (Fig.
4A), we noted a significant increase in Rmax and a substantial
reduction in EC50 at 6* OT nAChRs (Fig. 4B) comparing WT
and 6L9S mice (WT: Rmax  4.6  0.3 units, EC50  0.075 
0.025M; 6L9S: Rmax 14.7 0.7 units, EC50 0.015 0.004
M;Rmax: p 0.001; EC50: p 0.05) (Fig. 4G,H), consistent with
previous results (Drenan et al., 2008b). We noted a correspond-
ing decrease in Rmax at (non-6) 42* nAChRs (Fig. 4C) in
6L9SOT (WT:Rmax 14.5 0.5 units;6
L9S:Rmax 7.4 0.4
units; p 0.001) (Fig. 4G), but also saw a minor, yet significant
decrease in EC50 at these receptors as well (WT: EC50  0.53 
0.09 M; 6L9S: EC50  0.24  0.06 M; p  0.05) (Fig. 4H).
Thus, the apparent increase in 42* receptor (MII-resistant)
numbers (Fig. 3F) in 6L9S OT had no observed functional con-
sequence. Results for this genotype comparisonwere very similar in
ST(Fig. 4D) at62* (Fig. 4E) (WT:Rmax3.20.3units;6
L9S:
Rmax 6.6 0.5 units; p 0.001) (WT: EC50 0.031 0.017M;
6L9S: EC50 0.016 0.006M; p	 0.05) and (non-6)42*
Figure 3. Quantitative analysis of62* and42* receptor levels in ST and OT. A–C,CtxMII (50 nM) inhibition of [ 125I]-
epibatidine binding separates 62* and 42* subtypes in ST of WT, 6 L9S, 4KO, and 4KO/6 L9S mice. Membrane
preparations from ST of the indicated mice were incubated with [ 125I]epibatidine in the presence and absence of competing,
unlabeledCtxMII. Raw binding values (C) for MII-resistant (mainly42*) andMII-sensitive (mainly62*) receptors (A), as
well as percentage of MII-sensitive receptors (B) are shown. D–F, 62* and 42* receptor analysis for OT was performed
identical to ST (A–C). Data are expressed as mean SEM. The number of mice in each group was as follows: WT, n 7;6 L9S,
n 7;4KO, n 6;4KO/6 L9S, n 5. All statistically significant comparisons are indicated. *p 0.05, **p 0.01,
***p 0.001.
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nAChRs (Fig. 4F) (WT: Rmax 15.8 0.5 units; 6
L9S: Rmax
7.8 0.2 units; p 0.001) (WT: EC50 0.53 0.08M; 6
L9S:
EC50 0.35 0.03 M; p	 0.05) (Fig. 4D–H).
To study the effect of 4 subunit deletion on 6* nAChR
function, we compared DA release results between 4KO and
4KO/6L9S mice. Previous results with 4KO mice showed
decreased Rmax and increased EC50 compared to WT (Salminen
et al., 2007), results that were replicated in this study. For 6*
nAChRs in OT tissue (Fig. 4B), we noted only a slight increase in
Rmax for 4KO/6
L9S mice when compared to 4KO mice
(4KO: Rmax 3.83 0.13 units; 4KO/6
L9S: Rmax 5.24
0.24 units; p 0.001) (Fig. 4G). There was a significant reduction
in EC50 for 4KO/6
L9S compared to 4KO (4KO: EC50 
0.97 0.15M;4KO/6L9S: EC50 0.43 0.09M; p 0.01)
(Fig. 4H), but both values were at least one order of magnitude
greater than for either WT or 6L9S mice. Results in ST (Fig. 4E)
were similar for the4KObackground (4KO:Rmax 3.63 0.15
units; 4KO/6L9S: Rmax  4.16  0.06
units; p  0.01) (4KO: EC50  0.88 
0.16 M; 4KO/6L9S: EC50  0.25 
0.02 M; p  0.001) (Fig. 4G,H). Thus,
loss of 4 subunits from 6* nAChRs in
6L9S mice severely reduces the sensitiv-
ity of these receptors at DA nerve termi-
nals despite the presence of a sensitizing
serine residue at the M2 9 position. This
decisively shows that without 4 sub-
units, DA neurons cannot augment
their 62* receptor sensitivity by pro-
ducing increased numbers of receptors
with one or more L9S 6 subunit.
Burst firing selectively increases DA
release in6L9S dorsal striatum
The results obtained with synaptosomes
suggest that the hyperactivity observed in
6L9S mice, which is eliminated or sub-
stantially reduced upon removal of 4
subunits, is due to differences in ACh-
modulated DA release in striatum. Mid-
brain DA neurons exhibit both tonic and
phasic firing profiles, and the transition to
phasic firing is governed in part by pon-
tine cholinergic inputs to DA neuron cell
bodies (Lanc¸a et al., 2000). DAneuron fir-
ing properties, in turn, strongly influence
dopamine release. Therefore, we reasoned
that 6L9S mice may demonstrate alter-
ations in DA release as a result of 6*
nAChR hypersensitivity in DA neurons.
To study striatal DA release in a prep-
aration with intact DA fibers and func-
tional ACh-modulation of DA release, we
measured DA overflow with fast-scan cy-
clic voltammetry at carbon fiber elec-
trodes (CFEs) in coronal striatal slices
(Fig. 5A). We first calibrated the CFEs
with solutions of DA dissolved in ACSF.
Catecholamines such as DA and 5-HT
produce characteristic oxidation and re-
duction voltage peaks (Zhou et al., 2005).
DA detection was confirmed at our CFEs
based on oxidation currents at 600 mV
and reduction currents at200 mV, respectively (Fig. 5B, inset).
Responses to pure DA were linear at our CFEs in the range of
detection expected from striatal slices (0–5 M) (Fig. 5B). Elec-
trically evoked DA release from dorsal striatum in slices revealed
a voltammogram very similar to that of pure DA (Fig. 5C, inset).
Slice electrophysiological experiments in 6L9S tissue show
that nicotine administration increases firing in DA neurons, and
that spontaneous ACh release from cholinergic terminals pro-
duces a detectable activation of 6L9S* nAChRs on DA cell bod-
ies (Drenan et al., 2008b) (data not shown). Endogenous ACh or
exogenous nicotine may therefore augment DA neuron activity
and result in more burst firing in 6L9S mice. Alternatively (or
additionally), DA release frompresynaptic terminalsmay be aug-
mented due to enhanced activity of hypersensitive 6* receptors.
To determine the interplay between DA release and DA neuron
firing frequency, and to assess the role of 4 subunits, we mea-
sured DA release amplitude and kinetics in brain slices of WT,
Figure 4. Dopamine release from striatal presynaptic terminals is restored toWT levels in4KO/6 L9S mice. A–F, Hypersen-
sitive6* nAChR-mediated DA release in6 L9S OT (A–C) and ST (D–F ) is reversed by4 nAChR subunit deletion. OT or ST from
WT,6 L9S,4KO, and4KO/6 L9S mice was dissected and synaptosomes were prepared. DA release was stimulated with a
range of nicotine concentrations (1 nM, 3 nM, 10 nM, 30 nM, 100 nM, 300 nM, 1M, 10M, 100M, 300M), and a concentration–
response relation for eachmouse line is shown for total release (A,D). To determine the relative contribution of6* and non-6*
receptors, synaptosome sampleswere incubatedwithCtxMII (50 nM).CtxMII-sensitive (6* dependent) release is shown inB
andE, and6*-independent release is shown inCandF.G,H, QuantificationofDA releasemeasured inA–F forWT,6 L9S,4KO,
and4KO/6 L9S mice in ST and OT. Rmax (G) and EC50 (H ) forCtxMII-sensitive (62*) andCtxMII-resistant (42*) DA
release in ST and OT is shown. Data are expressed as mean SEM. The number of mice in each group was as follows: WT, n 7;
6 L9S,n7;4KO,n9;4KO/6 L9S,n10.All statistically significant comparisonsare indicated. *p0.05, **p0.01,
***p 0.001.
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6L9S and 4KO/6L9S mice. Because
6L9S mice display a locomotor pheno-
type (Figs. 1, 2), we focused our experi-
ments on dorsal striatum, the regionmost
strongly implicated in motor function
and the region dissected for the ST sam-
ples in the synaptosome experiments. We
measured absolute DA release following
single-pulse (1p) stimulation and four
pulse (4p, 100 Hz) burst stimulation,
which resembles the greatest firing rate for
DA neurons in mammals (Hyland et al.,
2002; Bayer and Glimcher, 2005). In WT
slices, we noted a marked short-term syn-
aptic depression for 4p stimulation com-
pared to 1p [Fig. 5C (left),D], which is
consistent with other reports using
acutely cut slices (Schmitz et al., 2002;
Rice and Cragg, 2004; Zhang and Sulzer,
2004; Exley et al., 2008). 6L9S slices dis-
played a substantial reduction in peak DA
release compared to WT 1p stimulation
(WT 1p: 0.92  0.06 M; 6L9S 1p:
0.34 0.05M; p 0.001) (Fig. 5C, mid-
dle panel). Unlike WT, however, 6L9S
slices did not show synaptic depression, as
peak DA responses following 4p stimula-
tion were significantly greater than for 1p
stimulation (WT: 1p  0.92  0.06 M;
4p  1.04  0.11 M; p 	 0.05) (6L9S:
1p  0.34  0.05 M; 4p  0.94  0.19
M; p  0.01) (Fig. 5C,D). Interestingly,
we noted only a slight reduction in peak
1p DA release in 4KO/6L9S mice com-
pared to WT (WT 1p: 0.92  0.06 M;
4KO/6L9S 1p: 0.70  0.08 M; p 
0.05) [Fig. 5C (right),D]. Removal of 4
subunits from 6L9S mice recapitulated
the synaptic depression phenomenon
seen in WT slices, as 4p stimulation was
slightly but not significantly elevated
compared to 1p stimulation in 4KO/
6L9S slices (4KO/6L9S: 1p  0.70 
0.08 M; 4p 0.97 0.11 M; p	 0.05)
[Fig. 5C (right),D]. Although neither 1p
nor 4p peak DA responses in 6L9S slices
exceeded those in WT slices, we noted
substantial alterations to the DA response
waveform (Fig. 5C, middle panel) in ex-
periments with 6L9S tissue. To better
understand the effect on DA waveforms caused by the 6L9S
mutation, we analyzed the responses in Figure 5C for 10–90%
rise time and decay time constant (). In WT slices, there was no
significant difference between 1p and 4p for rise time or  (rise
time:WT 1p 317 14ms;WT 4p 375 33ms; p	 0.05) (:
WT 1p 650 82 ms; WT 4p 842 268 ms; p	 0.05) (Fig.
5E,F). In contrast, rise time following 1p stimulation in 6L9S
slices was substantially elevated compared to 1p (or 4p) responses
inWT slices (6L9S: 1p 617 70 ms; WT: 1p 317 17 ms;
p 0.01) (6L9S: 1p 617 70ms;WT: 4p 375 33ms; p
0.01) (Fig. 5E). Further, there was an additional increase in rise
time for 4p responses compared to 1p in 6L9S slices (6L9S:
1p 617 70ms; 4p 804 28ms; p 0.05) (Fig. 5E).  values
were also significantly increased for 4p versus 1p stimulation in
6L9S slices (6L9S: 1p 824 164 ms; 4p 1990 221 ms;
p  0.01) (Fig. 5F), suggesting that extracellular DA persists in
6L9S dorsal striatum in response to a burst of action potentials.
4 subunits are apparently required for the effect seen in 6L9S
mice, as there was no significant effect on rise time or decay time
constant in 4KO/6L9S mice when we compared 1p and 4p
stimulation (rise time: 4KO/6L9S 1p 305 36 ms; 4KO/
6L9S 4p 362 59ms; p	 0.05) (:4KO/6L9S 1p 504
131ms;4KO/6L9S 4p 1019 271ms; p	 0.05) (Fig. 5E,F).
We did notice significant differences in the maximum decay
slope of the 1p and 4p responses among the three genotypes
studied. WT DA responses exhibited the fastest DA uptake (i.e.,
Figure 5. 4 subunits mediate selective potentiation of burst-evoked striatal DA release in6 L9S mice. A, Schematic of the
slice recording experiment. A carbon fiber recording electrode (CFE) was placed in the dorsal striatum (CPu; bregma0.4 mm),
and DA release was evoked with a bipolar stimulating electrode placed 200–300m from the recording site. B, Calibration and
testing of CFEs for DAdetection. To show that CFEDA responses in vitro are linear, peak oxidative currentwasmeasured in response
to bath solutions of 2.5M and 5.0M DA. A representative voltammogram is shown for an application of a solution of 5M
dopamine to the carbon fiber surface (inset). C, Altered DA release responses in6 L9S striatum are lost when4 nAChR subunits
are deleted. Coronal slices containing dorsal striatumwere stimulatedwith a bipolar electrode and DA releasewasmeasuredwith
fast scan cyclic voltammetry inWT,6 L9S, and4KO/6 L9S adultmice. Responses to 1 pulse (1p) and to 4p (100Hz) stimulation
were normalized to DA concentrationswith calibration curves (B) for each genotype. Plots for each average response are shown in
C. A representative voltammogram for evoked (1p) DA release in dorsal striatum is shown (inset). Scale bars: 300 nM DA, 500 ms.
D–G, Statistics of peak responses and kinetic parameters fromdata inC.D, PeakDA responses in6 L9S dorsal striatumare altered
compared to WT and4KO/6 L9S mice. The average peak DA concentration (M) for 1p and 4p stimulation is shown for each
genotype. E, Rise time is prolonged for 4p DA responses in6 L9S slices but is normalized by elimination of4 nAChR subunits. In
E, a box plot of 10–90% rise time for 1p and 4p DA responses is shown for WT, 6 L9S, and 4KO/6 L9S mice. F, Decay of
extracellular DA is delayed following 4p stimulation in dorsal striatum of6 L9S but not4KO/6 L9S mice. For each genotype
indicated,  was derived and plotted for mean 1p and 4p response curves (F ). G, The relative DA signal is selectively elevated in
6 L9S striatum. 1p and 4p responses for each indicated genotype were integrated (area under the curve) and normalized to the
WT 1p DA signal. For C–G, data are expressed as mean SEM. The number of recording sites for each group was as follows: WT,
n 11;6 L9S, n 14;4KO/6 L9S, n 10. All statistically significant comparisons are indicated. *p 0.05, **p 0.01,
***p 0.001.
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greatest negative-goingmaximum decay slope) (1p,0.00100
0.00007 M/ms; 4p, 0.00120  0.00017 M/ms), 6L9S re-
sponses were the slowest (1p, 0.00006  0.00003 M/ms; 4p,
0.00028  0.00002 M/ms), and 4KO/6L9S responses ex-
hibited an intermediate value (1p,0.00043 0.00008 M/ms;
4p, 0.00053  0.00011 M/ms). Maximum decay slope indi-
cates the speed of DA uptake at a saturating concentration of DA,
thus these differencesmay reflect changes inDA transporterVmax
(see Discussion). The prolonged decay kinetics seen in 1p and 4p
DA release responses in 6L9S slices (Fig. 5F) suggested that the
integrated DA response in these mice may differ more substantially
than peak measurements would suggest.
Area-under-the-curvemeasurements (Zhang
et al., 2009) for 1p and 4p responses in the
three genotypes under study were nor-
malized to WT 1p responses. Unlike WT
and 4KO/6L9S slices, 6L9S slices
showed a significantly elevated 4p DA re-
sponse compared to 1p stimulation (WT:
1p  1.0  0.06; 4p  1.0  0.14; p 	
0.05) (6L9S: 1p 0.5 0.1; 4p 1.6
0.3; p 0.001) (4KO/6L9S: 1p 0.8
0.1; 4p 1.1 0.2; p	 0.05) (Fig. 5G).
To further isolate and study the effect
of the 6L9S mutation and DA neuron
firing frequency on evoked DA rele-
ase, we conducted paired-pulse experi-
ments. In dorsal striatum, DA release
displays marked short-term synaptic de-
pression when pulses are paired at fre-
quencies from 1 to 100 Hz (Cragg, 2003;
Rice and Cragg, 2004; Zhang and Sulzer,
2004). In nucleus accumbens, however,
initial release probability is lower but
paired-pulse depression is not as severe
(Cragg, 2003; Zhang et al., 2009). In WT
dorsal striatum, we also measured signifi-
cant synaptic depression comparing a first
pulse ( p1; 0.89  0.21 M DA) with a
second ( p2; 0.09 0.05MDA) (Fig. 6A,
left). In contrast, experiments in 6L9S
slices revealed no synaptic depression, as
peak [DA]o was approximately equivalent
for p1 (0.20  0.03 M DA) and p2
(0.19  0.05 M DA) (Fig. 6A, middle).
This lack of synaptic depression was re-
flected in a significantly increased paired-
pulse ratio for 6L9S mice versus WT
(WT: 0.13 0.06;6L9S: 0.67 0.15; p
0.01) (Fig. 6B). Again, the gain in synap-
tic facilitation afforded by the 6L9S
mutation was completely reversed by loss
of 4 subunits: 4KO/6L9S p1 peak DA
(0.85 0.13MDA) returned toWT lev-
els, p2 responses (0.14  0.10 M DA)
were similar to those seen in WT, and the
paired-pulse ratio for 4KO/6L9S re-
lease (0.12 0.09) was comparable toWT
(Fig. 6A,B). Thus, together, these electro-
chemical experiments suggest that pat-
terns of tonic and phasic activity in DA
neuron firing in 6L9S mice results in
substantially altered patterns of DA re-
lease, from reduced DA release during tonic firing to augmented
synaptic DA during phasic firing.
DA release and uptake, as well as a variety ofmouse behaviors,
can be influenced by alterations in components of the DA system
such as D1-class and D2-class dopamine receptors and the dopa-
mine transporter (DAT). In particular,DA synaptic lifetime in ST
is strongly influenced by the rate of uptake by DAT (Giros et al.,
1996; Zhuang et al., 2001; Rice and Cragg, 2008). Further, mice
lacking D2 receptors have a decreased peak and duration of DA
release in response to single pulses (Schmitz et al., 2002). To
determine whether any substantial alterations in these compo-
Figure 6. Altered DA release probability in 6 L9S dorsal striatum. A, Reduced initial release probability and elimination of
paired-pulse depression in6 L9S striatum. Coronal slices fromWT,6 L9S and4KO/6 L9S mice were alternately stimulated
with 1 pulse (1p) or 2 pulses (2p). 1p waveforms are measured directly as p1 data, while the p2 waveform was isolated by
subtracting average 1pwaveforms from average 2pwaveforms over several trials. Average p1 and p2waveforms for the indicated
genotypes are shown in A. Calibration: 300 nM DA, 500ms. B, Increased paired-pulse ratio in6 L9S mice versus WT controls and
4KO/6 L9S mice. For each dataset in A, paired-pulse ratio was calculated as p2/p1. Data are expressed as mean SEM. The
number of recording sites for each group was as follows: WT, n 9; 6 L9S, n 11; 4KO/6 L9S, n 9. All statistically
significant comparisons are indicated. **p 0.01.
Figure 7. Normal DA transporter and DA receptor number and function in 6 L9S and 4KO/6 L9S mice. A–C, Normal
DA-related pharmacological parameters in6 L9S and4KO/6 L9Smice as determined by DAT and DA receptor ligand binding.
Brain regions (OT and ST) fromWT,6 L9S,4KO, and4KO/6 L9S mice were dissected and labeled with the indicated ligand
followed bywashout and quantification by scintillation counting. Raw binding values are indicated as fmol/mg protein formazin-
dol (DAT ligand), SCH23390 (D1 receptor ligand), and raclopride (D2 receptor ligand). D, E, Normal DA transporter function in
6 L9S and4KO/6 L9S mice. Synaptosomes were prepared as in Figure 2, but [ 3H]dopamine uptake was assayed at 50 nM (D)
or 1M (E) [DA]o for all genotypes. F, Ratio of DAT activity at 1M (“high”) versus 50 nM (“low”) [DA]o. Data are ratios of the values
in D and E. Data are expressed as mean SEM. The number of mice in each group was as follows: n 9;6 L9S, n 9;4KO,
n 8;4KO/6 L9S, n 8. All statistically significant comparisons are indicated. *p 0.05.
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nents of the DA system might account for our behavioral or
physiological results, we measured DAT and D1 and D2 DA re-
ceptors by ligand binding in tissue homogenates. In ST, there
were no differences in DAT levels as determined by [3H]-
mazindol binding (Fig. 7A), whereas we did note an increase in
DAT levels in 6L9S OT versus WT OT (WT  1083  102
fmol/mg protein; 6L9S  1503  191 fmol/mg protein; p 
0.05) (Fig. 7A). For D1-class receptors, there was no statistically
significant difference in [3H]SCH23390 ligand binding for any
genotype comparison in either OT or ST (Fig. 7B). Similarly,
there was also no significant difference in D2-class receptors
(measured with [3H]raclopride) in OT or ST for any genotype
comparison (Fig. 7C). We took note of the overall reduction in
DAT and D2 receptor levels in the ventral relative to dorsal stria-
tum, which is consistent with a recent report (Lammel et al.,
2008). To directly measure DAT function in vitro, we performed
DAT uptake assays using synaptosomes similar to those used for
DA release. Using established methods for determining DAT
function (Grady et al., 2002), we estimated DAT KM to be 80 nM
DA (data not shown), which was consistent with previous studies
(Giros et al., 1996; Parish et al., 2005). At a [DA]o close to the KM
(50 nM), and at a maximal [DA]o (1M), there was little effect on
DA uptake for any genotype comparison (Fig. 7D,E). Interest-
ingly, these two concentrations of DA roughly correspond to the
EC50 for activation of D2 and D1 receptors, respectively. There
was a significant difference between 4KO and 4KO/6L9S
only in OT but not ST, and only at 1.0M [DA]o (4KO 6.4
0.8 pmol of DA/g protein/min; 4KO/6L9S 4.3 0.4 pmol
of DA/g protein/min; p 0.05) (Fig. 7E). There was no differ-
ence in either brain region for any genotype comparison for the
1.0M [DA]o (20KM)/0.05M [DA]o (KM) ratio of uptake
rates (Fig. 7F).
Discussion
Overall, these data are consistent with the idea that cholinergic
control over DA release exerts greater influence in 6L9S mice
due to 6* nAChR hypersensitivity (Fig. 8). Similar to other in
vitro electrochemistry studies, we show that in WT dorsal stria-
tum, single stimulus pulses or brief trains in DA fibers elicit sim-
ilar levels of DA release due to short-term synaptic depression
(Fig. 8A). Several reports show that decreased presynaptic
nAChR activity, via desensitization, pharmacological blockade,
or decreased ACh release from striatal cholinergic interneurons,
can alter short-term depression and enhance the difference in
efficacy between single pulses and bursts (Zhou et al., 2001; Rice
and Cragg, 2004; Zhang and Sulzer, 2004; Threlfell et al., 2010).
In this study, increased nAChR function can also enhance this
difference. In mice with hypersensitive 6L9S* nAChRs, single
APs combinewith nAChR activity to result in reducedDA release
(Fig. 8B). In these mice, however, released DA is present for
longer periods (Fig. 5E,F), paired-pulse depression (PPD) is re-
duced (Fig. 6B), and bursts of APs lead tomore overall DA release
(Fig. 5G).
In some respects, our electrochemistry results in dorsal stria-
tum, where DA release following single-pulse stimulation in
6L9S slices is reduced and PPD in relieved relative to WT and
4KO/6L9S tissue, resembles experiments where nAChR activ-
ity is blocked before DA fiber stimulation. Indeed, reducing stri-
atal nAChR activity with desensitizing applications of nicotine or
antagonists such as dihydro--erythroidine (DHE) or
mecamylamine results in less DA release in response to a single
stimulus (Zhou et al., 2001; Rice and Cragg, 2004; Zhang and
Sulzer, 2004). These studies also demonstrate that PPD is sub-
stantially reduced when nAChR activity is eliminated by these
applications. We see a similar result in 6L9S slices relative to
WT: reduced peakDA release following single stimulations (Figs.
5C, 6A). We also noted that the DA release profile in 6L9S
dorsal striatum is similar in some respects to the profile in DAD2
receptor KOmice. In these mice, as in ours, DA release following
single-pulse stimulation is reduced relative toWTmice (Schmitz
et al., 2002). Interestingly, our results in 6L9S dorsal striatum
more closely resemble the normal pattern ofDA release in ventral
striatum of mice and primates. Electrochemical recordings in
nucleus accumbens shell of mice (Zhang et al., 2009) or primates
(Cragg, 2003) reveals that ventral regions of the striatum are
characterized by reduced peak DA release following single stim-
ulation, and paired-pulse results showing little PPD or even
paired-pulse facilitation. This is thought to occur via differences
in Ca2 availability in presynaptic terminals of these two brain
areas. Thus, in some respects our DA release results in 6L9S
mice are quite similar to various studies, including reports using
pharmacological agents or other genetic mutations to manipu-
late the DA system, as well as reports in different species.
In other respects, however, our electrochemical results differ
from previous studies. For example, whereas many studies in-
volving elimination of nAChR activity demonstrate that brief
trains (e.g., 4p) result in augmented peakDA release compared to
identical stimulations under control conditions (Rice and Cragg,
2004; Exley et al., 2008; Zhang et al., 2009), we did not see an
Figure8. Hypersensitive6*nAChRsmediate sustained burst-evokedDA release in6 L9S
mouse striatum. A, Single pulse and burst firing in DA fibers of WT mice. DA release from DA
terminals is governed by the pattern of firing activity in DA axons (single pulse vs burst). Local
ACh from cholinergic interneurons acts at presynaptic nAChRs, including6*, to modulate the
probability of release. B, Single pulse and burst firing in DA fibers of6 L9S mice. Based on the
data presentedhere, single pulses inDA fibers collaboratewith nAChRactivity in the terminal to
reduce the 1p DA response. The combination of (1) a burst of APs and (2) ACh-driven activation
of hypersensitive 6* receptors results in augmented DA release compared to single-pulse
stimulation.
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increase in peak DA relative to WT slices following 4p stimulus
protocols (Fig. 5D).Most importantly, though, DAwaveforms in
6L9S dorsal striatum display novel kinetics. We report that DA
responses in 6L9S dorsal striatum are slower to reach peak con-
centration (Fig. 5E), and also decay more slowly following cessa-
tion of the stimulus (Fig. 5F). These effects onDAkinetics are not
seen in studies where nAChR activity is altered with pharmaco-
logical agents, and are typically only apparent when theDA trans-
porter is genetically eliminated/reduced, or pharmacologically
blocked (Giros et al., 1996; Zhuang et al., 2001; Cragg, 2003;
Senior et al., 2008; Zhang et al., 2009).
What causes the altered DA release pattern seen in 6L9S
dorsal striatum? ACh release from cholinergic interneurons, per-
haps augmented by electrical stimulation of the tissue, may play a
role in 6L9S altered DA release, likely via differences in receptor
sensitivity to ligand (Fig. 4H). Although intrinsic differences in
ACh release probability (and consequent 6* nAChR activation)
by cholinergic interneurons in intact 6L9S versus WT mice are
possible, WT and 6L9S cholinergic interneurons have equiva-
lent firing rates and largely similarmembrane properties (Drenan
et al., 2008b). We cannot rule out that compensatory or adaptive
mechanisms, operating as the animals mature, might cause the
reduced 1p release and/or prolonged release kinetics. For in-
stance, 6L9S presynaptic terminals may have undergone a
change in their channel repertoire that renders them hypersensi-
tive to repetitive stimulation. Changes in the ratio of 4*(non-
6)/6* function, which are present in 6L9S mice, may be such
an adaptation. Alternatively, the reduction in peak DA release
following single and/or burst stimulation may be an adaptive
response to the prolonged release kinetics, similar to DAT KO
mice (Giros et al., 1996).
In a previous study, we showed that hypersensitive 6L9S
channels are tonically active in DA neuron somata (Drenan et al.,
2008b), suggesting that tonic cholinergic input to midbrain DA
areasmay depolarizeDAneurons and/or increase their firing rate
in vivo. Furthermore, ligand-gated cation currents through
6L9S channels in these cells are prolonged compared to their
WT counterparts (Drenan et al., 2008b), which reflects the sig-
nificant increase in single channel burst duration in nAChRswith
L9S mutations (Labarca et al., 1995). In striatum, presynaptic
and/or axonal 6L9S channels may similarly depolarize DA fi-
bers/terminals due to these changes at the single channel level.
Axonal depolarization can significantly alter the action potential
waveform (Shu et al., 2006; Kole et al., 2007), and tonic depolar-
ization of the presynaptic terminal would be expected to reduce
Vmax for the DA transporter (Huang et al., 1999), resulting in
slower DA reuptake following release. Indeed, in PC12 cells ex-
pressing DAT and nAChRs, nAChR activation resulted in mem-
brane depolarization and a reduction in DAT uptake velocity
(Huang et al., 1999). Although our DAT binding and functional
experiments show that there are no intrinsic differences in DAT
expression levels or enzymatic function in vitro in the four geno-
types examined (Fig. 7), they do not address the possibility that
6L9S channels depolarize DA fibers and reduce DAT func-
tion in slices and/or in vivo. Alternatively, 6L9S DA fibers
may have normal resting membrane potentials but undergo
prolonged depolarization (due to activation of 6L9S chan-
nels by ACh) during electrical stimulation of the slice, result-
ing in extended periods of slowed DAT uptake velocity during
the time scale of our measurements.
Future studies are needed to fully determine the mechanism
that gives rise to the alterations inDA release seen in6L9S dorsal
striatum. It is important to note that, unlike in vitro slice experi-
ments, studies of DA release in vivo are characterized by much
smaller DA signals (Michael and Wightman, 1999) and do not
show substantial synaptic depression (Chergui et al., 1994). Thus,
it will be important to study DA neuron firing and DA release in
awake, behaving 6L9S mice in future studies. Nevertheless,
these alterations along with changes in excitability of DA neuron
cell bodies inmidbrain are sufficient to cause the complex behav-
ioral phenotypes that were observed in 6L9S mice. We suggest
that 6L9S mouse behavioral hyperactivity results from both (1)
a more efficacious action of ACh on DA neuron dendrites and
somata harboring hypersensitive 642* channels, resulting in
more phasic firing, and (2) DA fibers in striatum that have more
effective frequency filtering (Exley and Cragg, 2008; Exley et al.,
2008), where activation of 6L9S channels by ACh permits DA
fibers to diminish their output in response to tonic firing yet
augment DA release in response to bouts of phasic firing. In
contrast to other recent studies that amplify and isolate phasic
DA neuron firing to alter DA-dependent behaviors with gene
knock-outs (Zweifel et al., 2009) and optogenetics (Tsai et al.,
2009), we show that the cholinergic system can bemanipulated to
alter DA release and modify a variety of behaviors in mammals.
More specifically, this study demonstrates the importance of
642*nAChRs in governing cholinergic control overDA release,
and reinforces the idea that compounds capableof selectively target-
ing 642* nAChRs could be useful in manipulating the DA
system in disorders such as nicotine dependence, PD, schizo-
phrenia, or attention deficit hyperactivity disorder. Such drug
therapies that regulate dopaminergic output via modification of
somatic and/or presynaptic 642* receptors may give better
outcomes than DA agonists or DA replacement therapies, as the
natural spatiotemporal activity patterns of DA neurons would be
better preserved. For example, stimulating DA release with
642* selective compounds in PD may alleviate dyskinesias
associated with L-Dopa therapy if coadministration of the
nAChR compound allowed the clinician to reduce the necessary
dose of L-Dopa (Quik and McIntosh, 2006; Quik et al., 2008;
Bordia et al., 2010).
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